News
GSK to pay $1.2B upfront to Boston Pharmaceuticals for efimosfermin alfa, a MASH drug candidate. Deal includes $800M in ...
AbbVie partners with ADARx Pharmaceuticals in $335M upfront deal for siRNA tech collaboration across neuroscience, immunology ...
HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and ...
Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...
The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...
Jiangsu Hengrui, a 55-year-old drugmaker that has become one of China’s leading forces in biotech, expects net proceeds of about 9.4 billion Hong Kong dollars … ...
Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...
Plus, news about Allogene, Kyverna, Sernova, ADC Therapeutics, Acelyrin, Alumis, Atara, Lava Therapeutics and Repare Therapeutics ...
Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...
Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...
An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a ...
Bayer cuts 2,000 jobs in Q1 2025, reaching 11,000 total layoffs amid reorganization. CEO Bill Anderson reports strong pharma ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback